Yazar "Tulunay, Gokhan" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Body Mass Index is Associated with Immunohistochemical Nuclear Phosphatase and Tensin Homolog Deleted on Chromosome 10 (PTEN) Expression in Stage IB-IC Endometrioid Endometrial Carcinoma
    (Galenos Yayincilik, 2007) Meydanli, Mutlu; Karadag, Nese; Kose, Faruk; Tulunay, Gokhan; Ozfuttu, Ahrnet
    Objective: To examine the relationship between clinicopathologic features and nuclear phosphatase and tensin homolog deleted on chromosome 10 (PTEN) expression in a homogeneous group of Stage IB-IC sporadic endometrioid endometrial cancer (EEC) patients. Materials and Methods: This study was conducted on 65 consecutive EEC patients with FIGO Stage IB-IC disease who underwent initial complete surgical staging. Age, body mass index (BMI), tumor grade, immunohistochemical nuclear PTEN expression and clinical outcome were examined. The median follow-up period was 49 months (range, 8 to 78 months). Results: Immunohistochemical staining revealed positive nuclear PTEN expression in 20 cases (30.8%). Nuclear PTEN was found out to be reduced in 36 cases (55.4%), whereas it was completely lost in nine cases (13.8%). After evaluating the staining status, 45 cases (69.2%) were judged as negative for nuclear PTEN expression. During the follow-up period, clinical recurrence of disease was documented in five of 65 women (7.7%). The 5-year disease free survival rate for patients with positive nuclear PTEN expression was similar to that for patients with negative nuclear PTEN expression (75.2% vs. 91.3%, respectively; p =0.728 [log-rank test]). The mean body mass index (BMI) of positive nuclear PTEN expressing cases was significantly greater than that of patients with negative nuclear PTEN expression (32.5 +/- 6.5 vs. 28.5 +/- 5.0, respectively; p =0.009). Discussion: Lost/reduced nuclear PTEN expression was frequent in FIGO Stage IB/IC EEC. BMI is the only clinicopathologic variable affecting immunohistochemical nuclear PTEN expression.
  • Küçük Resim Yok
    Öğe
    Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma
    (Future Drugs Ltd, 2006) Kose, M. Faruk; Meydanli, M. Mutlu; Tulunay, Gokhan
    Although the general intent of treatment for patients with recurrent ovarian cancer is palliative, and cure does not seem to be a realistic objective in this setting, median overall survival is greater than 12 months in platinum-sensitive recurrent ovarian cancer. Patients with ovarian cancer can now expect that the time from first relapse of their disease to death will be longer than the period from diagnosis to that first relapse. There is current evidence from prospective randomized trials that carboplatin combined with either paclitaxel or gemcitabine confers a progression-free survival advantage over platinum monotherapy for patients with platinum-sensitive relapsed ovarian cancer. Since the efficacy of paclitaxel/platinum and gemcitabine/carboplatin regimens appears to be comparable based on similar progression-free survival (both combinations confer a 3-month advantage), toxicity profiles should be taken into account when deciding on the combination to be used. The gemcitabine/carboplatin combination should be preferred in patients with underlying peripheral neuropathy. Since alopecia associated with paclitaxel can diminish the overall quality of life, the gemcitabine plus carboplatin combination may be preferable for patients in whom alopecia is a major consideration. This review provides an update on the role of the gemcitabine/carboplatin combination in platinum-sensitive recurrent ovarian cancer.